Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefepime Hydrochloride

FDA-approved product (injectable, injection), marketed as Cefepime And Dextrose In Duplex Container, Cefepime Hydrochloride, Cefepime Hydrochloride In Plastic Container and 2 more.

Registered studies
50+
Lab records
203
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefepime Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacteriemia
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sprain
  • Urinary tract infection
  • Ventilator-associated pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fourth-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DE01

Repurposing investigation

Cefepime Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 95 of 203 lab records
Open Cefepime Hydrochloride in ChEMBL Registered studies below
Show the latest 150 of 203 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefepime Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Antibiotic Choice On ReNal Outcomes (ACORN)

    NCT05094154 · start 2021-11-10

    Registered record
    Registry ID
    NCT05094154
    Conditions
    Sepsis; AKI; Neurotoxicity
    Interventions
    anti-pseudomonal cephalosporin; anti-pseudomonal penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-10
    Completion
    2022-10-21
    Enrolment
    2,634

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; AKI; Neurotoxicity
    Interventionanti-pseudomonal cephalosporin; anti-pseudomonal penicillin
    PhasePhase 4
    Registry statusCompleted

  • Antibiotics Continuous Infusion at Home

    NCT04816968 · start 2021-09

    Registered record
    Registry ID
    NCT04816968
    Conditions
    Severe Bacterial Infections
    Interventions
    Cefepime; Piperacillin/tazobactam; Meropenem; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-09
    Completion
    2023-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Bacterial Infections
    InterventionCefepime; Piperacillin/tazobactam; Meropenem; Vancomycin
    PhasePhase 1
    Registry statusUnknown

  • SYN-004 Safety and Tolerability in Allo-HCT Subjects

    NCT04692181 · start 2021-02-15

    Registered record
    Registry ID
    NCT04692181
    Conditions
    Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
    Interventions
    SYN-004, Ribaxamase or Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-02-15
    Completion
    2030-09-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
    InterventionSYN-004, Ribaxamase or Placebo
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)

    NCT04033029 · start 2021-01-01

    Registered record
    Registry ID
    NCT04033029
    Conditions
    Hemodiafiltration; Sepsis; Acute Kidney Injury
    Interventions
    Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®); Antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2023-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodiafiltration; Sepsis; Acute Kidney Injury
    InterventionContinuous venovenous hemodiafiltration with high adsorption membrane (oXiris®); Antibiotics
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

    NCT04042233 · start 2019-12-31

    Registered record
    Registry ID
    NCT04042233
    Conditions
    Prosthetic Joint Infection; Vancomycin; Joint Diseases
    Interventions
    Experimental Intraosseous vancomycin 500mg in 250 mL NS; Standard IV administration of vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-31
    Completion
    2022-09-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection; Vancomycin; Joint Diseases
    InterventionExperimental Intraosseous vancomycin 500mg in 250 mL NS; Standard IV administration of vancomycin
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

    NCT03840148 · start 2019-08-07

    Registered record
    Registry ID
    NCT03840148
    Conditions
    Urinary Tract Infections; Acute Pyelonephritis
    Interventions
    Cefepime/VNRX-5133 (taniborbactam); Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-08-07
    Completion
    2021-12-14
    Enrolment
    661

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Acute Pyelonephritis
    InterventionCefepime/VNRX-5133 (taniborbactam); Meropenem
    PhasePhase 3
    Registry statusCompleted

  • Association of Cefepime Trough Levels With Clinical Efficacy and Neurotoxicity in Patients With Febrile Neutropenia

    NCT04250038 · start 2019-08-01

    Registered record
    Registry ID
    NCT04250038
    Conditions
    Pharmacokinetics; Pharmacodynamics; Cefepime
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-08-01
    Completion
    2021-05-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Pharmacodynamics; Cefepime
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section

    NCT04009772 · start 2019-07-01

    Registered record
    Registry ID
    NCT04009772
    Conditions
    Emergency Cesarean Section; Infection Wound
    Interventions
    Cefepime; Cefuroxime plus Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-07-01
    Completion
    2020-03-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergency Cesarean Section; Infection Wound
    InterventionCefepime; Cefuroxime plus Metronidazole
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring

    NCT03790631 · start 2019-01-14

    Registered record
    Registry ID
    NCT03790631
    Conditions
    Beta-lactam Antibiotics; Therapeutic Drug Monitoring; Toxicity; Efficacy; Imipenem; Meropenem; Piperacillin; Flucloxacillin; Amoxicillin; Ceftazidime; Cefepime
    Interventions
    The study is observational.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-14
    Completion
    2023-12-31
    Enrolment
    771

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBeta-lactam Antibiotics; Therapeutic Drug Monitoring; Toxicity; Efficacy +7 more
    InterventionThe study is observational.
    PhaseNot recorded
    Registry statusCompleted

  • Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection

    NCT03850860 · start 2018-12-01

    Registered record
    Registry ID
    NCT03850860
    Conditions
    Bone and Joint Infection
    Interventions
    empirical antibiotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-01
    Completion
    2019-06-01
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone and Joint Infection
    Interventionempirical antibiotherapy
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

    NCT03687255 · start 2018-09-24

    Registered record
    Registry ID
    NCT03687255
    Conditions
    Urinary Tract Infections
    Interventions
    cefepime/AAI101 combination; Piperacillin/tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-24
    Completion
    2020-02-15
    Enrolment
    1,043

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    Interventioncefepime/AAI101 combination; Piperacillin/tazobactam
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

    NCT03485950 · start 2018-05-16

    Registered record
    Registry ID
    NCT03485950
    Conditions
    Other Infectious Diseases
    Interventions
    Cefepime; Ceftolozane; Laboratory Biomarker Analysis; Meropenem; Piperacillin-Tazobactam; Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-16
    Completion
    2022-02-16
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOther Infectious Diseases
    InterventionCefepime; Ceftolozane; Laboratory Biomarker Analysis; Meropenem +2 more
    PhasePhase 2
    Registry statusCompleted

  • To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

    NCT03622008 · start 2018-03-23

    Registered record
    Registry ID
    NCT03622008
    Conditions
    Antibiotics Causing Adverse Effects in Therapeutic Use
    Interventions
    FEP-TAZ 4 g; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-23
    Completion
    2018-05-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotics Causing Adverse Effects in Therapeutic Use
    InterventionFEP-TAZ 4 g; Placebo
    PhasePhase 1
    Registry statusCompleted

  • BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU

    NCT03147807 · start 2017-10-20

    Registered record
    Registry ID
    NCT03147807
    Conditions
    Pneumonia; Urinary Tract Infections; Bloodstream Infection
    Interventions
    betaLACTA® rapid diagnostic test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2019-10-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Urinary Tract Infections; Bloodstream Infection
    InterventionbetaLACTA® rapid diagnostic test
    PhaseNot applicable
    Registry statusCompleted